Patent US5085985A successfully refreshed from Google Patents.
US5085985A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibodies and their use in a method for monitoring subsets of activated T cells
Assignee: Becton Dickinson and Co
•
Filing: 1987-11-12
•
Granted: 1992-02-04
•
Expires: 2007-11-12
Abstract
Abstract Monoclonal antibodies which recognize activated T lymphocytes are secreted by hybridomas produced by conventinal fusion and selection methodology following immunization of mice with a human lymphocyte fraction containing T lymphocytes activated by a mitrogen or an antigen. The monoclonal antibodies are used in a method to monitor subsets of activated T lymphocytes present, for example, from a patient's blood.
Inventors
- 👤 Vernon C. Maino
- 👤 Marina E. Janszen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 20:17
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56966; G01N33/56972; G01N2474/00; G01N2474/20; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S435/973
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
155 words
A method for monitoring subpopulations of activated T lymphocytes in a sample comprising the steps of: (a) isolating a cell sample containing activated T lymphocytes; (b) combining said cell sample with a first monoclonal antibody selected from the group consisting of anti L-35 (ATCC HB 9050) and anti L-36 (ATCC HB 9051), said first monoclonal antibody being conjugated to a first fluorescent dye, and with a second monoclonal antibody selected from the group consisting of anti-CD5, anti-CD8, anti-CD4 and anti-CD3 monoclonal antibodies, said second monoclonal antibody being conjugated to a second fluorescent dye, said first and second fluorescent dyes having emission wavelengths which differ a sufficient amount to produce separately detectable signals, wherein said first and second monoclonal antibodies bind to said activated T lymphocytes; (c) detecting fluorescence emission from said first and second fluorescent dyes; and (d) monitoring subpopulations of activated T lymphocytes in said sample as a function of said detected fluorescence emission.
Claim 2
Independent Claim
155 words
A method for monitoring subpopulations of activated T lymphocytes in a sample comprising the steps of: (a) isolating a cell sample containing activated T lymphocytes; (b) combining said cell sample with a first monoclonal antibody selected from the group consisting of anti L-35 (ATCC HB 9050) and anti L-36 (ATCC HB 9051), said first monoclonal antibody being conjugated to a first fluorescent dye, and with a second monoclonal antibody selected from the group consisting of anti-CD5, anti-CD8, anti-CD4 and anti-CD3 monoclonal antibodies, said second monoclonal antibody being conjugated to a second fluorescent dye, said first and second fluorescent dyes having emission wavelengths which differ a sufficient amount to produce separately detectable signals, wherein said first and second monoclonal antibodies bind to said activated T lymphocytes; (c) detecting fluorescence emission from said first and second fluorescent dyes; and (d) monitoring subpopulations of activated T lymphocytes in said sample as a function of said detected fluorescence emission.
Claim 3
Dependent Claim
20 words
The method in accordance with claim 1 wherein said cell sample is isolated from said sample by density gradient separation.
Claim 4
Dependent Claim
31 words
The method in accordance with claim 1 wherein said first and second fluorescent dyes are selected from the group of dyes consisting of fluorescein, rhodamine, Texas Red, phycoerythrin B and allophycocyanin.
Claim 5
Dependent Claim
14 words
The method in accordance with claim 3 wherein said first fluorescent dye is fluorescein.
Claim 6
Dependent Claim
15 words
The method in accordance with claim 3 wherein said second fluorescent dye is phycoerythrin B.
Claim 7
Dependent Claim
13 words
The method of claim 1 wherein the sample is isolated from peripheral blood.
Claim 8
Independent Claim
91 words
A method for monitoring subpopulations of activated leukocytes in a cell sample comprising the steps of: (a) combining a cell sample containing activated leukocytes with a monoclonal antibody conjugated to a detectable label, said antibody being selected from the group consisting of anti L-35 (ATCC HB 9050) and anti L-36 (ATTCC HB 9051), where said monoclonal antibody binds to said activated leukocytes; (b) causing said label to provide a detectable signal; (c) detecting said signal; and (d) monitoring subpopulations of activated leukocytes in said cell sample by characteristics of said signal.
Claim 9
Independent Claim
91 words
A method for monitoring subpopulations of activated leukocytes in a cell sample comprising the steps of: (a) combining a cell sample containing activated leukocytes with a monoclonal antibody conjugated to a detectable label, said antibody being selected from the group consisting of anti L-35 (ATCC HB 9050) and anti L-36 (ATTCC HB 9051), where said monoclonal antibody binds to said activated leukocytes; (b) causing said label to provide a detectable signal; (c) detecting said signal; and (d) monitoring subpopulations of activated leukocytes in said cell sample by characteristics of said signal.
Claim 10
Dependent Claim
19 words
The method in accordance with claim 7 wherein said cell sample is isolated from a human peripheral blood sample.
Claim 11
Dependent Claim
20 words
The method in accordance with claim 7 wherein said label is a fluorescent dye and said signal is fluorescence emission.
Claim 12
Dependent Claim
31 words
The method in accordance with claim 7 wherein said label is an enzyme and said signal is associated with a change in color of a substrate upon which said enzyme acts.
Claim 13
Dependent Claim
12 words
The method in accordance with claim 7 wherein said label is gold.
Claim 14
Independent Claim
121 words
A method for monitoring subpopulations of activated human T lymphocytes in a sample comprising the steps of: (a) isolating a cell sample containing activated T lymphocytes from a human blood sample; (b) combining said cell sample with a monoclonal antibody selected from the group consisting of anti L-35 (ATTCC HA 9050) and anti L-36 (ATCC HB 9051), said antibody being conjugated to fluorescein, and with an anti-CD3 monoclonal antibody, said anti-CD3 being conjugated to phycoerythrin B, whereby said antibodies bind to said activated T lymphocytes to give labeled T lymphocytes; (c) detecting two-color fluorescence emission from said labeled T lymphocytes; and (d) monitoring subpopulations of activated T lymphocytes in said blood sample as a function of said detected two-color fluorescence emission.
Claim 15
Independent Claim
121 words
A method for monitoring subpopulations of activated human T lymphocytes in a sample comprising the steps of: (a) isolating a cell sample containing activated T lymphocytes from a human blood sample; (b) combining said cell sample with a monoclonal antibody selected from the group consisting of anti L-35 (ATTCC HA 9050) and anti L-36 (ATCC HB 9051), said antibody being conjugated to fluorescein, and with an anti-CD3 monoclonal antibody, said anti-CD3 being conjugated to phycoerythrin B, whereby said antibodies bind to said activated T lymphocytes to give labeled T lymphocytes; (c) detecting two-color fluorescence emission from said labeled T lymphocytes; and (d) monitoring subpopulations of activated T lymphocytes in said blood sample as a function of said detected two-color fluorescence emission.
Claim 16
Independent Claim
180 words
A method for monitoring subpopulations of activated T lymphocytes in a body tissue comprising the steps of: (a) isolating a sample of a body tissue containing activated T lymphoctyes having antigens expressed on the surfaces thereof; (b) adding to said tissue a first monoclonal antibody selected from the group consisting of anti L-35 (ATCC HB 9050) and anti L-36 (ATCC HB 9051), said first antibody being conjugated to a first fluorescent dye, and a second monoclonal antibody selected from the group consisting of anti-CD5, anti-CD8, anti-CD4 and anti-CD3 monoclonal antibodies, said second antibody being conjugated to a second fluorescent dye, said first and second dyes having emission wavelengths which differ by at least 25 nm, wherein said antigens on said activated T lymphocytes bind to said first and second antibodies to give labeled T lymphocytes; (c) subjecting said labeled T lymphocytes to excitation light to cause fluorescence from said labeled T lymphocytes; (d) detecting fluorescence emission from said labeled T lymphocytes; and (e) monitoring subpopulations of activated T lymphocytes in said tissue as a function of said detected fluorescence emission.
Claim 17
Independent Claim
180 words
A method for monitoring subpopulations of activated T lymphocytes in a body tissue comprising the steps of: (a) isolating a sample of a body tissue containing activated T lymphoctyes having antigens expressed on the surfaces thereof; (b) adding to said tissue a first monoclonal antibody selected from the group consisting of anti L-35 (ATCC HB 9050) and anti L-36 (ATCC HB 9051), said first antibody being conjugated to a first fluorescent dye, and a second monoclonal antibody selected from the group consisting of anti-CD5, anti-CD8, anti-CD4 and anti-CD3 monoclonal antibodies, said second antibody being conjugated to a second fluorescent dye, said first and second dyes having emission wavelengths which differ by at least 25 nm, wherein said antigens on said activated T lymphocytes bind to said first and second antibodies to give labeled T lymphocytes; (c) subjecting said labeled T lymphocytes to excitation light to cause fluorescence from said labeled T lymphocytes; (d) detecting fluorescence emission from said labeled T lymphocytes; and (e) monitoring subpopulations of activated T lymphocytes in said tissue as a function of said detected fluorescence emission.
References Cited (Backward Citations)
US4515894A
Cited
US4515895A
Cited
US4515893A
Cited
US4364932A
Cited
US4364934A
Cited
US4626507A
Cited
GB2095258A
Cited
US4550086A
Cited
US4599304A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-02-03 | 1995-08-05 | 1996-02-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-02-03 | 1999-08-05 | 2000-02-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-02-03 | 2003-08-05 | 2004-02-04 | $7700.00 | Window Closed / Lapsed |